AltStreet
EDGAR Verified
Primary Source · SEC.gov

GLACIER BASIN BIOTECH FUND LLC

CIK 0001997850Fund Vehicle2023 vintage506(b), 3(c)(1)

Raised

Pre-open

Investors

—

Min Invest

$50,000

AltStreet Analysis

·

Generated from EDGAR primary sources

Glacier Basin Biotech Fund LLC is a Delaware pooled investment fund filed October 19, 2023, by executive officer Matthew McLoughlin under Rule 506(b) and Section 3(c)(1). The filing indicates pre-open status with no capital raised or investor count disclosed; minimum investment is set at $50,000. The fund targets longevity biotech investments and appears to operate independently without identified parent platforms or related entities.

This longevity biotech fund employs the standard 506(b) private placement exemption combined with 3(c)(1) status, consistent with the majority of private biotech investment vehicles. The $50,000 minimum investment threshold positions it at the retail-accessible end of the spectrum for specialized biotech funds, which typically range from $25K for emerging managers to $1M+ for established institutional platforms.

Data Flags

generalPre-open filing with no disclosed first sale date for a sub-$100M offering
related_entitiesNo related EDGAR entities found despite platform-style naming convention suggesting potential for multiple vehicles
states_of_solicitationStates of solicitation not specified on 506(b) filing, which typically requires state-by-state disclosure

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001997850
Entity NameGLACIER BASIN BIOTECH FUND LLC
Exemption506(b), 3(c)(1)
First Sale Date—
Filing DateOctober 19, 2023
Accession Number0001997850-23-000001
Total Amount Sold—
Total Investors—
Minimum Investment$50,000
Securities TypePooled Investment Fund
State of IncorporationNot specified
Amendment CountOriginal filing only

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

MATTHEW MCLOUGHLIN

Executive Officer · WOODINVILLE, WA

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Claim Profile — FreeGet Verified — $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.